Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Cell Therapy Group Company Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals sector. GONZALES, JOSEPHINE MARIA is the 1 distinct examiner assigned to this case, representing the busiest examiner with 1 busiest examiner pending action. This activity is limited to 1 distinct art unit, showing a concentrated effort in a specific area of biotechnology.
The data reveals a prosecution profile where 1 pending office action is the only active matter at the USPTO. Because GONZALES, JOSEPHINE MARIA is the 1 distinct examiner involved, the company's success in the Biotechnology & Pharmaceuticals area currently depends on this single relationship. The 1 busiest examiner pending action matches the total pending count, leaving no room for examiner diversification. Practitioners should note that the matching count of 1 pending office action and 1 distinct examiner within 1 distinct art unit allows for a very focused prosecution strategy. However, this also means that any rejection from GONZALES, JOSEPHINE MARIA affects the entire active portfolio. Navigating this 1 distinct art unit requires a deep understanding of its specific trends, as there are no other pending actions to provide broader context.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GONZALES, JOSEPHINE MARIA | 1 | 28.8% | +34.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17758128 | Cell Expressing Immune Modulatory Molecules and System for Expressing Immune Modulatory Molecules | GONZALES, JOSEPHINE MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17758128 | Cell Expressing Immune Modulatory Molecules and System for Expressing Immune Modulatory Molecules | GONZALES, JOSEPHINE MARIA | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17758128 | Cell Expressing Immune Modulatory Molecules and System for Expressing Immune Modulatory Molecules | GONZALES, JOSEPHINE MARIA | 1631 | §103 | Final Rejection | — | Pending | Jun 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Cell Therapy Group Company Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Josephine Maria Gonzales has the most, with 1 of Shanghai Cell Therapy Group Company Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
